Maravai LifeSciences Holdings, Inc.

telephone keypad. If you would like to withdraw your question, again, press the star 1. Thank you. I'd now like to turn the call over to Debra Hart, Head of Investor Relations. You may begin.

Good afternoon, everyone.

Thanks for joining us on our second quarter 2024 earnings call. Our press release and the slides accompanying today's call are posted on our website and available at investors.maravai.com. As you can see on our agenda for today on slide two, Trey will provide a business update, and Kevin will review our financial results and guidance. Drew Burch, President of Nucleic Acid Production, and Becky Buzio, our Chief Commercial Officer, will join the call for the question and answer session following the prepared remarks. During today's call, management will make forward-looking statements. It is possible that actual results could differ from management's expectations. we refer you to slide three for more detail on forward-looking statements. Also, during this call, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in the press release and also posted to the investor section of our website. Please also refer to MARVI's SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I'll turn the call over to Trey.